Kevin Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Tran has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- William Fraser Symmans
Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publications - Alberto de la Cruz
Centro Oncológico de Galicia 14 La Coruña, La Coruña
5 shared publications - Ana Santaballa
Department of Medical Oncology, La Fe University Hospital, IISLaFe, Valencia, Spain
5 shared publications - Antonio Antón-Torres
Hospital Universitario Miguel Servet 15 Zaragoza
5 shared publications - Cesar Augusto Rodriguez
Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
5 shared publications - Cristina Reboredo
University Hospital A Coruña (XXIAC-SERGAS)
5 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360239
Quantifying the diagnostic time gap in precision oncology: A retrospective analysis of potential time savings from same-day cartridge-based molecular testing versus next-generation sequencing in cytology specimens
Background: Next-generation sequencing (NGS) turnaround times (TAT) exceed two weeks and can delay the initiation of targeted therapy. Rapid cartridge-based platforms such as Idylla deliver single-gene or fusion results from minimal cytology material within hours, but time savings have not been systematically quantified. Methods: Forty-two cases of non-small cell lung carcinoma, thyroid carcinoma, melanoma, and mammary analogue secretory carcinoma of the salivary gland that underwent both Idylla testing ( KRAS , EGFR , BRAF, and GeneFusion assays) and orthogonal NGS at a single academic center were reviewed. NGS TAT was calculated from specimen collection to report release, and Idylla results were modeled as available one day after collection. The primary outcome was per-case time savings (NGS TAT minus one day); treatment timelines were reconstructed from the medical record. Analyses were descriptive; no inferential testing was performed. A sensitivity analysis varied the modeled Idylla TAT from 1 to 3 days, and an adjusted estimate assigned no time saving to the two cartridge results that were not actionable on the day of collection. Results: The median NGS TAT across all 42 cases was 20.0 days (IQR, 17.0–23.8; range, 8–51). Against the modeled 1-day Idylla TAT, the median time savings was 19.0 days per case (IQR, 16.0–22.8; range, 7–50), totaling 858 patient-days. Assigning no time saving to those two cases gave a median of 18.0 days and 817 patient-days. No patient received therapy that was subsequently contradicted by the sequencing result. In thirteen patients, the sequencing interval alone exceeded three weeks, and in seven, no systemic therapy was underway while the result was awaited. Conclusions: Same-day cartridge-based testing from cytology and small biopsy specimens could provide actionable results a median of 19 days earlier than standard NGS. Whether this translates into earlier treatment initiation was not assessed and requires prospective evaluation.
- 16 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360239
Open AccessQuantifying the diagnostic time gap in precision oncology: A retrospective analysis of potential time savings from same-day cartridge-based molecular testing versus next-generation sequencing in cytology specimens
Background: Next-generation sequencing (NGS) turnaround times (TAT) exceed two weeks and can delay the initiation of targeted therapy. Rapid cartridge-based platforms such as Idylla deliver single-gene or fusion results from minimal cytology material within hours, but time savings have not been systematically quantified. Methods: Forty-two cases of non-small cell lung carcinoma, thyroid carcinoma, melanoma, and mammary analogue secretory carcinoma of the salivary gland that underwent both Idylla testing ( KRAS , EGFR , BRAF, and GeneFusion assays) and orthogonal NGS at a single academic center were reviewed. NGS TAT was calculated from specimen collection to report release, and Idylla results were modeled as available one day after collection. The primary outcome was per-case time savings (NGS TAT minus one day); treatment timelines were reconstructed from the medical record. Analyses were descriptive; no inferential testing was performed. A sensitivity analysis varied the modeled Idylla TAT from 1 to 3 days, and an adjusted estimate assigned no time saving to the two cartridge results that were not actionable on the day of collection. Results: The median NGS TAT across all 42 cases was 20.0 days (IQR, 17.0–23.8; range, 8–51). Against the modeled 1-day Idylla TAT, the median time savings was 19.0 days per case (IQR, 16.0–22.8; range, 7–50), totaling 858 patient-days. Assigning no time saving to those two cases gave a median of 18.0 days and 817 patient-days. No patient received therapy that was subsequently contradicted by the sequencing result. In thirteen patients, the sequencing interval alone exceeded three weeks, and in seven, no systemic therapy was underway while the result was awaited. Conclusions: Same-day cartridge-based testing from cytology and small biopsy specimens could provide actionable results a median of 19 days earlier than standard NGS. Whether this translates into earlier treatment initiation was not assessed and requires prospective evaluation.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Forest plot for the GEICAM/9906 translational study cohort primary endpoint of DRFI, on the FEC vs FEC + P arms for SETER/PR cutpoint “0.75” categories.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Representativeness of Study Participants.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Patient and baseline characteristics of GEICAM/9906 hormone receptor positive (HR+) breast cancer cohort.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Bivariable Cox regression analysis of DRFI between SETER/PR index and EPclin risk score in the GEICAM/9906 translational study cohort.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor–Positive Breast Cancer in the GEICAM/9906 Trial
Bivariable Cox regression analysis of DRFI between SETER/PR index and EPclin risk score in the GEICAM/9906 translational study cohort.
- Open Access
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3870-3879
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor–positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. Experimental Design: We conducted a blinded, prospective–retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant FEC followed by weekly paclitaxel (FEC+P) versus six cycles of FEC in lymph node–positive breast cancer. SETER/PR index was measured in all available HR+/HER2– tumor RNA samples using a pre-specified cutpoint (<0.75). The primary endpoint was distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS). Results: Of 647 HR+/HER2– tumors, 567 (87.6%) passed assay quality control (279 FEC+P; 288 FEC). Low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (p=0.046). Among patients with low SETER/PR index, FEC+P significantly improved DRFI (HR 0.46; 95% CI, 0.22–0.95; p=0.035), with similar results after adjustment (HR 0.48; 95% CI, 0.24–1.00; p=0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR 1.02; 95% CI, 0.70–1.47; p=0.931). Differences in OS and BCSS did not reach significance. Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2– breast cancer. These findings independently validate SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection.
- 26 May 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (17) , 3870-3879
Open AccessSensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Purpose: To independently validate that low endocrine transcriptional activity measured by SETER/PR index in hormone receptor–positive breast cancer predicts benefit from dose-dense paclitaxel chemotherapy within a second prospective-retrospective biomarker study. Experimental Design: We conducted a blinded, prospective–retrospective biomarker analysis within the GEICAM/9906 trial (NCT00129922), which compared adjuvant FEC followed by weekly paclitaxel (FEC+P) versus six cycles of FEC in lymph node–positive breast cancer. SETER/PR index was measured in all available HR+/HER2– tumor RNA samples using a pre-specified cutpoint (<0.75). The primary endpoint was distant recurrence–free interval (DRFI); secondary endpoints were overall survival (OS) and breast cancer–specific survival (BCSS). Results: Of 647 HR+/HER2– tumors, 567 (87.6%) passed assay quality control (279 FEC+P; 288 FEC). Low SETER/PR index was identified in 92 tumors (16.2%). There was a significant interaction between SETER/PR status and treatment on DRFI (p=0.046). Among patients with low SETER/PR index, FEC+P significantly improved DRFI (HR 0.46; 95% CI, 0.22–0.95; p=0.035), with similar results after adjustment (HR 0.48; 95% CI, 0.24–1.00; p=0.049). No treatment benefit was observed for SETER/PR ≥0.75 (HR 1.02; 95% CI, 0.70–1.47; p=0.931). Differences in OS and BCSS did not reach significance. Conclusions: Low endocrine transcriptional activity predicts benefit from adding weekly paclitaxel to anthracycline-based adjuvant chemotherapy in HR+/HER2– breast cancer. These findings independently validate SETER/PR index as a predictive biomarker for paclitaxel-based chemotherapy and support its potential role in guiding regimen selection.